Spirogen was founded in August 2000 to commercialise its scientific founders' research into DNA binding molecules. Professors David Thurston and John Hartley and their colleague Dr Philip Howard had been working on DNA-interacting agents for over 10 years when they met entrepreneur Dr Chris Martin and formed the company.
| August 2000 | Spirogen founded |
| October 2001 |
Spirogen moves to The School of Pharmacy and University College London |
| December 2001 |
Spirogen officially opened by Lord Sainsbury of Turville at The School of Pharmacy, London |
| March 2001 |
First round of funding |
| May 2003 |
Ipsen licenses SG2000 (SJG-136) Second round of funding from Ipsen Ltd and Research Corporation Technologies (RCT) Entered into Research Agreement with Ipsen in the field of Gene Targeting |
| April 2004 |
SG2000 enters Phase 1 Clinical Trials in the UK First patient dosed in the UK with SG2000 (SJG-136) |
| April 2004 |
Professor Moses Lee appointed as Scientific Consultant |
| January 2005 |
Dr. Fran Crawford appointed as Chief Operating Officer |
| February 2005 |
First patient dosed in the USA with SG 2000 (SJG-136) |
| September 2006 |
Dr Barrie Ward appointed as Chairman of the Board of Directors |
| January 2008 |
Vanderbilt-Ingram Cancer Centre recruits final patient in Phase I trial |
